-
American Nobel laureate in medicine hopes to illuminate the brain
-
Tens of thousands expected in Paris for high school protests
-
Trump approves firing squad for convicted US military base shooter
-
AI borrowing binge rattles US markets
-
Grappling with 'homework scams,' US universities shun AI detectors
-
Young Canadians sue government over alleged climate failures
-
Separatists win Quebec election in test for Canada PM
-
White Sox down Guardians to take 2-0 series lead
-
Leaders visit Pacific atoll at frontline of climate change
-
NHL record-breaker Ovechkin says current season will be his last
-
Yemen's Houthis claim striking Riyadh airport, other Saudi sites
-
France roar back in Nations League as Italy beat Turkey
-
Best-selling British author Jeffrey Archer dies aged 86
-
Messi readies for final farewell in Argentina send-off
-
Military plane crash kills 32 in Nigeria
-
Esposito seals Italy win over Turkey in Nations League
-
Olise powers France to win over Belgium in Nations League
-
Russia downplays plague reports as Trump offers US help
-
High-flying Blazy turns to birdlife at Chanel
-
Trump says US moved bombers from UK base after 'threats'
-
Riyadh's allies pledge troops as Yemen, Saudi Arabia attack Houthis
-
Brazilian stocks surge to record after Bolsonaro election lead
-
Clashes erupt outside Kosovo parliament over war crimes court
-
Leaders to visit Pacific atoll at frontline of climate change
-
Milan's Saelemaekers suffers ankle setback, faces lengthy spell out
-
ICC gives more details about arrest warrants for Taliban ministers
-
Rubio arrives in Iceland to push for greater US presence in Arctic
-
Nigeria's Tinubu confirms 32 dead after military plane crash
-
Putin allows Italy's UniCredit to sell part of Russian business
-
'Reckless' AI firms can't control models, says whistleblower
-
Djokovic into China Open final as Medvedev out for hitting fan with ball
-
Switching on brain cells: the Nobel-winning science of optogenetics
-
ICC unseals arrest warrants for Taliban education ministers
-
Quebec votes as separatist surge poses test for Canada PM
-
Modric hopes fans back Croatia against Spain after England shame
-
Euro slides as concerns about French debt mount
-
Bolsonaro rides right-wing surge into Brazil's election runoff
-
Former Trump press secretary Leavitt joins Fox News
-
Turkey blocks X account of British reporter
-
Djokovic advances to China Open final as Medvedev out for hitting fan with ball
-
Ukraine says using AI robot guns to shoot down new Russian drones
-
Disgraced former US House speaker dies at 84
-
At Oct 7 memorial, Netanyahu says will be no Hamas rule in Gaza
-
Euro slides as worries about French debt grow
-
Ukraine blames Russia for deadly sinking of Turkish ship in Black Sea
-
US withdraws all bomber aircraft from UK airbase
-
UN rights council slams Taliban's 'oppression' of women
-
Drone hits Ethiopia IDP camp as fears grow of regional war
-
Norway eyes partial ban of smart glasses
-
US-German trio wins medicine Nobel for illuminating the brain
Hypha Labs Targets Disruptive Mushroom Active Ingredient Production
Eight-Day Cycles and Potential 80% Cost Savings
LAS VEGAS, NV / ACCESS Newswire / October 5, 2026 / The global functional mushroom market is estimated to reach $42.27 billion in 2026 and projected to grow to $95.95 billion by 2033, according to Grand View Research. Hypha Labs, Inc. is developing a disruptive biomanufacturing platform to address a critical challenge within this expanding industry: producing mushroom-derived active ingredients faster, more consistently, and at lower cost.
Hypha Labs' Mushroom Accelerator™ platform is designed to produce mushroom-derived biological material in approximately eight days, compared with the approximately 90-day conventional cultivation benchmark described by the company. Its developing commercial platform targets potential operational and production cost savings of up to 80% through automation, reduced labor requirements, a smaller production footprint, and minimized biological waste.
The platform's proprietary Micropearls™ provide biological starting material for downstream extraction and formulation of mushroom-derived active ingredients used in nutraceuticals, supplements, functional beverages, and research applications. Controlled bioreactor production is designed to improve batch consistency and make downstream processing more predictable.
Hypha Labs' collaboration with Mycology Resources combines its production technology with mushroom genetics, analytical capabilities, and extraction expertise to support commercial scale-up. The objective is a repeatable supply platform for manufacturers seeking consistent mushroom-derived ingredients.
By combining accelerated production with substantial potential cost reductions, Hypha Labs aims to change the economics of mushroom active ingredient manufacturing.
About Hypha Labs, Inc.
Hypha Labs, Inc. (OTCQB:FUNI) is developing proprietary automated mushroom production technologies designed to improve scalability, consistency, and manufacturing efficiency for the rapidly growing functional mushroom industry.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.
From time to time, the Company may post new material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit
www.HyphaLabs.com
For the Company's current Investor Presentation please visit
www.HyphaLabs.com/deck
Contact
Hypha Labs, Inc.
702 744 0640
[email protected]
SOURCE: Hypha Labs, Inc.
View the original press release on ACCESS Newswire
N.Mitchell--AT